 |
 |
 |
 |
 |
 |
 |
Oncology Trials
The Oncology Research Program, in partnership with local oncologists, offers patients access to leading-edge clinical trials sponsored by the National Cancer Institute's Cooperative Group Program or by pharmaceutical companies. These clinical trials study investigational drugs, new combinations of standard treatments for cancer, or cancer prevention in high risk patients.
For more information, please contact Suburban Hospital Oncology Research:
Barbara Squiller |
Melissa Hyman |
For information about clinical trials, visit the National Cancer Institute.
BREAST |
|
| NCIC CTG MA.32 | A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
|
| NSABP B47 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer |
Roche/Genentech BO22589 |
A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER2-positive progressive or recurrent locally advanced or metastatic breast cancer (MBC). (MARIANNE)
|